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ABSTRACT 
Background: Plant N-alkylamides (NAAs) are bio-active compounds with a broad functional 
spectrum.  In  order  to  reach  their  pharmacodynamic  targets,  they  have  to  overcome  several 
barriers of the body in the absorption phase. The permeability kinetics of spilanthol (a diene 
NAA) and pellitorine (a triene NAA) across these barriers (i.e. skin, oral/gut mucosa, blood-
brain barrier) were investigated.  
 
Methods: The skin and oral mucosa permeability were investigated using human skin and pig 
mucosa in an ex vivo in vitro Franz diffusion cell set-up. The gut absorption characteristics were 
examined using the in vitro Caco-2 cell monolayer test system. The initial blood-brain barrier 
transport kinetics were investigated in an in vivo mice model using multiple time regression and 
efflux  experiments.  Quantification  of  both  NAAs  was  conducted  using  HPLC-UV  and  bio-
analytical UPLC-MS methods. 
 
Results: We demonstrated  that spilanthol and pellitorine are able to  penetrate the skin  after 
topical administration. It is likely that spilanthol and pellitorine can pass the endothelial gut as 
they easily pass the Caco-2 cells in the monolayer model. It has been shown that spilanthol also 
crosses the oral mucosa as well as the blood-brain barrier.   
 
Conclusion: It was demonstrated that NAAs pass various physiological barriers i.e. the skin, oral 
and gut mucosa, and after having reached the systemic circulation, also the blood-brain barrier. 
As such, NAAs are cosmenutriceuticals which can be active in the brain. 
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1. INTRODUCTION  
The biomedical interest in N-alkylamides (NAAs), a large group of secondary metabolites found 
in various medicinal plants, has increased enormously. These compounds, occurring in more 
than 25 plant families, have a wide structural diversity and are potential lead compounds for 
functional food, cosmetics and medicines, as well as biocidal and plant protection products. They 
are  known  to  have  analgesic,  antimicrobial,  insecticidal,  sensory,  anti-inflammatory  and 
immune-modulating properties and are  traditionally  used to  treat  toothache, skin  and  gastric 
diseases, sexual dysfunctions and viral infections. Besides these ethnopharmacological uses in 
traditional  medicine,  plants  containing  NAAs  are  also  used  as  spices  for  their  pungent  and 
tingling sensations, and are incorporated in topical cosmetics for their wrinkle smoothing, anti-
aging properties. These compounds have thus a broad biofunctional spectrum interacting with 
different targets via several mechanisms (promiscuous pharmacodynamics) [1-7].  
A chemical and functional database (online available), Alkamid
®, was previously developed 
to  give  a  clear  overview  of  the  botanical  occurrence  of  NAAs  in  the  plant  families,  their 
chemistry,  physico-chemical  properties  and  the  biofunctionalities  [1].  The  different  N-
alkylamides possess a wide structural diversity with a central peptide bond as common feature. 
Generally, the plant NAAs consist of an aliphatic chain of poly-unsaturated fatty acids linked to 
a short-chain amine. Our NAA structural classification is build up from these two parts, starting 
with ‘‘F’’ (indicative for fatty acids part) followed by the fatty acid category (from 1 to 13) and 
ends with ‘‘M’’ (indicative for the amino part) followed by the amino category (from 1 to 13). 
Combining  the  F  part  with  the  M  part  yields  thus  different  chemical  NAA  classes  (FxMy 
nomenclature). 
Spilanthol (affinin) is an F3M1 N-alkylamide belonging to the Asteracea plant family and is 
present in several species of Spilanthes, e.g. acmella, in which it is the best known and most 
abundant compound. Pellitorine (F3M1 NAA) occurs in different plant families, including also 
the Asteracea family  Anthemideae tribe,  Anacyclus genus  and  pyrethrum  species. Spilanthol 
(deca-2E,6Z,8E-trienoic acid isobutylamide) is a triene, while pellitorine (deca-2E,4E-dienoic 
acid isobutylamide) only possesses two unsaturated carbon bonds (diene). The structures of these 
particular NAAs are given in Figure 1.  
NAAs can be orally or dermally administered (Figure 1). However, several physiological 
barriers, present in the human body, can complicate or prevent the absorption of NAAs into the 
general blood circulation (Figure 1). When topically applied, NAAs must be able to penetrate the 
stratum corneum, the outer layer of the skin, and reach the viable cells of the epidermis and 
underlying  dermis  with  its  blood  vessels  in  order  to  obtain  a  biological  effect.  After  oral 
administration, NAAs must be absorbed from the gastrointestinal lumen, thereby passing the oral 
and/or  intestinal  mucosal  barriers.  Previous  research  by  our  group  already  indicated  the 
successful dermal administration of NAAs thereby reaching the general blood circulation [8-10]. 
Moreover, Matthias et al. (2004) already investigated the transport of selected N-alkylamides 
present in Echinacea through the Caco-2 cell monolayer model: after 90 minutes, more than 50% 
of the NAAs penetrated the monolayer, indicating the functionality of oral administration as well 
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Once in the general circulation, NAAs have theoretically the possibility to diffuse across the 
blood-brain barrier (BBB), where they can elicit desirable but also unwanted central nervous 
system (CNS) effects. Several CNS diseases (e.g. epilepsy or neurodegenerative disorders) are 
currently still hard to treat, and one of the development hurdles is the impermeable BBB, making 
it  difficult  for  drugs  to  cross  this  barrier.  Woelkart  et  al.  (2009)  demonstrated  that  dodeca-
2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides (tetraenes originating from  Echinacea),  orally 
given to rats, are bioavailable with a rapid passage across the blood-brain barrier [12]. These 
results suggest a possible action of plant NAAs within the central nervous system.   
 
 
Figure 1: Overview pharmacokinetics of NAAs 
 
Our general goal was to further elucidate the possible human functionalities of plant NAAs 
by  a  quantitative  distribution  pharmacokinetic  investigation.  Our  hypothesis  was  that  plant 
NAAs do pass the different biological barriers. Therefore, NAAs with different structures, e.g. 
spilanthol, a triene NAA, and pellitorine, a diene NAA, were topically applied on mucosa and 
skin to evaluate their penetration and permeability. The gut absorption was investigated as well, 
using  the  in  vitro  Caco-2  monolayer  model.  In  addition,  blood-brain  barrier  transport  of 
spilanthol in mice was also examined. Based on these results, an overall conclusion was drawn 
related  to  oral  and  intestinal  mucosal,  dermal  and  blood-brain  barrier  permeability 
characteristics, indicating possible effects of NAAs in the central nervous system.  Functional Foods in Health and Disease 2014; 4(6):264-275                                                            Page 267 of 275 
 
 
2. MATERIALS  
2.1. Products examined 
The Spilanthes acmella extract (label claim: 30 % w/w spilanthol in ethanol) was a generous gift 
of Robertet (Grasse, France), while the Anacyclus pyrethrum extract, originating from India, was 
prepared and characterised as previously described [13].  The  spilanthol dose solutions used in 
the  Franz  diffusion  cell  experiments  are  described  in  detail  by  Boonen  et  al.  [8,9].  Briefly, 
different commercial formulations  were used (Indolphar
®,  Buccaldol
®,  A. Vogel
® Spilanthes 
acmella extract), as well as spilanthol dissolved in propylene glycol and ethanol. Pellitorine was 
dissolved  in  an  ethanol-water  solution  for  topical  administration  [15].  The  spilanthol  and 
pellitorine dose solutions for the Caco-2 cell experiment were prepared in Hanks’ balanced salt 
solution, containing maximum 0.5% ethanol. For the blood-brain barrier experiment, spilanthol 
was dissolved in ethanol, dimethylacetamide, tween and lactated ringer’s solution with bovine 
serum albumin [16].      
 
3. METHODS  
3.1. In vitro skin permeation study 
The transmucosal behaviour of spilanthol was evaluated using porcine buccal mucosa, while the 
transdermal behaviour of spilanthol and pellitorine was analysed using human skin in a Franz 
diffusion cell (FDC) set-up [8-10, 14, 15]. In brief, static Franz diffusion cells with a receptor 
compartment of 5 ml and an available diffusion area of 0.64 cm² were used to determine the skin 
permeation kinetics of the N-alkylamides. The transbuccal and transdermal experiments with 
spilanthol were performed six and four times, respectively. The FDC experiment with pellitorine 
was done in fourfold. 500 µl of the dose solutions were applied on the skin surface with a 
micropipette. The donor chamber was covered with parafilm to prevent evaporation of the dose 
formulations. During the FDC experiment, the temperature of the receptor compartment was kept 
constant at 32 °C by a water jacket. 200 µl aliquots of receptor fluid were taken at regular time 
intervals from the sample port and were immediately replaced by 200 µl of fresh receptor fluid. 
A linear relationship of the individual cumulative amount of the N-alkylamides versus time was 
observed, and steady state sink conditions were confirmed by these data. Quantification of the N-
alkylamides  in  the  samples  was  done  using  a  high-throughput  validated  High  Performance 
Liquid Chromatography – Ultraviolet (HPLC-UV) method. 
 
3.2. In vitro permeation study in Caco-2 monolayers  
The  gut  mucosa  kinetics  of  spilanthol  and  pellitorine  were  investigated  using  a  Caco-2  cell 
intestinal model [16]. This was performed in duplicate for each N-alkylamide. Briefly, the Caco-
2 cells were grown to a monolayer on 0.4 µm polycarbonate membranes. Transport experiments 
were carried out in both the apical-to-basolateral and the basolateral-to-apical directions. Final 
sample volumes of 0.4 ml apically and 1.2 ml basolaterally for 12-mm filter supports during the 
transport experiment were used. Samples were taken at 15, 30, 60, 90 and 120 minutes from the 
acceptor  solution  and  were  immediately  replaced  by  fresh  Hank’s  balanced  salt  solution. 
Quantification  of  the  NAAs  was  conducted  using  bio-analytical  Ultra  Performance  Liquid 
Chromatography – Mass Spectroscopy (UPLC-MS) techniques. Functional Foods in Health and Disease 2014; 4(6):264-275                                                            Page 268 of 275 
 
 
3.3. In vivo blood-brain barrier (BBB) experiment  
3.3. 1. Multiple time regression 
The  initial  blood-brain  barrier  rate  kinetics  were  investigated  using  multiple  time  regression 
(MTR) in an in vivo mice model [16-18]. Briefly, after mice were anesthetized, the spilanthol 
dose solution was injected in the jugular vein. At specified time points, blood was obtained from 
the carotid artery. Immediately after blood collection, the mice were sacrificed and brains were 
collected.  
 
3.3. 1. Efflux study 
The  efflux  method  was  used  to  study  the  brain-to-blood  transport  [16-18].  After  mice  were 
anesthetized, the spilanthol dose solution was stereotactically injected into the lateral ventricle of 
the brain. Blood was collected from the abdominal aorta at regular time points after which the 
mice were immediately sacrificed and the brains isolated. 
Quantification of the NAAs in brain and serum samples was conducted using bio-analytical 
LC-MS techniques. Sample preparation was first performed using solid-phase extraction (HLB 
oasis  µElution  96  well  plate).  Thereafter,  the  samples  were  injected  into  an  Acquity  UPLC 
coupled to a MS Xevo™ TQ-S mass spectrometer (Waters) with electrospray ionization source 
and a triple quadrupole mass analyser. A reversed phase C18 Acquity UPLC column was used 
with a water-methanol gradient. 
 
4. RESULTS  
4.1. Permeability through skin and oral mucosa 
When spilanthol was topically applied on buccal mucosa, systemic effects can be expected next 
to local mucosa effects as spilanthol was able to significantly penetrate through buccal mucosa. 
Depending on the formulation applied as dose solution (e.g. as commercially available products, 
ethanolic extract or dissolved in propylene glycol/H2O mixtures), permeability coefficient (Kp) 
values ranging between 5.3 and 47.5 x 10
-3 cm/h were observed [8].  
Spilanthol penetrates through the human stratum corneum and the viable epidermis as well, 
thereby reaching the dermis and thus the systemic circulation, with Kp values between 0.6 and 
53.3  x  10
-4  cm/h,  depending  on  i.a.  the  used  dose  formulation  [9].  An  overview  of  the 
experimentally determined permeability coefficients is given in Table 1.  
 
Table 1: Skin and oral mucosa permeability coefficients of spilanthol in different formulations 
[8,9]  
 
Transmucosal data 
Formulation  Receptor fluid 
Kp (x 10
-3 cm/h) ± SEM  
(n=5-6) 
Indolphar® 
PBS + HPCD 
19.52 ± 1.75 
Buccaldol®  47.53 ± 2.90 
Ethanolic extract  5.28 ± 0.60 
10% PG  10.89 ± 0.42 Functional Foods in Health and Disease 2014; 4(6):264-275                                                            Page 269 of 275 
 
 
30% PG  11.70 ± 0.94 
Transdermal data 
Formulation  Receptor fluid 
Kp (x 10
-4 cm/h) ± SEM  
(n=3-4) 
65% EtOH 
PBS  4.38 ± 1.41 
PBS + HPCD  4.38 ± 1.42 
EtOH/H2O  0.70 ± 0.12 
10% PG 
PBS  15.34 ± 0.86 
PBS + HPCD  16.62 ± 0.92 
EtOH/H2O  5.46 ± 0.78 
A. Vogel
® Spilanthes 
acmella commercial extract 
PBS  3.56 ± 1.09 
PBS + HPCD  4.95 ± 1.65 
EtOH/H2O  0.64 ± 0.16 
10% EtOH 
PBS + HPCD 
37.88 ± 1.82 
30% EtOH  53.29 ± 3.49 
65% EtOH  6.59 ± 1.56 
10% PG  31.50 ± 3.37 
30% PG  22.67 ± 2.49 
65% PG  2.94 ± 0.47 
 
PBS:  phosphate  buffered  saline,  PG:  propylene  glycol,  EtOH:  ethanol,  H2O:  water,  HPCD: 
hydroxypropyl beta-cyclodextrin.  
 
Similarly,  also  pellitorine  penetrates  the  human  skin,  as  observed  in  the  experimentally 
determined  flux  curves  (Figure  2)  plotting  the  percentage  of  the  applied  dose  solution  of 
pellitorine permeated through the skin against time [15].  
 
 
Figure 2: Transdermal kinetics of pellitorine (mean ± SEM, n=4) 
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4.2. Gut absorption 
Spilanthol  and  pellitorine  were  found  to  diffuse  rapidly  through  Caco-2  monolayers  [16]. 
Transport  was  observed  in  both  directions,  i.e.  apical-to-basolateral  and  basolateral-to-apical 
transport.  Figures  3  and  4  show  the  percentage  of  the  applied  dose  solution  of  spilanthol 
permeated through the Caco-2 monolayer against the time (duplicate). Spilanthol is clearly able 
to  permeate  the  Caco-2  monolayer  in  both  directions,  with  a  higher  amount  of  intestinal 
absorption (apical-basolateral) compared to blood efflux (basolateral-apical).   
 
 
Figure 3: Apical-basolateral transport of spilanthol (mean ± SEM, n=2) 
 
 
 
Figure 4: Basolateral-apical transport of spilanthol (mean ± SEM, n=2) 
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The apical-basolateral and the basolateral-apical transport of pellitorine is given in Figures 5 
and 6.  
 
 
Figure 5: Apical-basolateral transport of pellitorine (mean ± SEM, n=2) 
 
 
 
Figure 6: Basolateral-apical transport of pellitorine (mean ± SEM, n=2) 
 
4.3. Blood-brain barrier transport 
Our multiple time regression experiments indicate that spilanthol passes the blood-brain barrier: 
the relationship between the brain/serum concentration ratio and the exposure time is presented 
in Figure 7. A rapid but highly significant influx of spilanthol into the brains is observed, with 
plateauing already after 10 minutes exposure time. 
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                  Figure 7: Brain influx results (MTR in mice)  
 
When investigating the transport of spilanthol out of the brain into the blood, it is confirmed 
that there is also efflux of spilanthol (and no complete brain trapping), possibly explaining the 
rapid plateauing observed at the influx experiment (Figure 8).  
 
 
                  Figure 8: Brain efflux of spilanthol  
 
 
5. DISCUSSION  
In  this  study,  we  have  shown  that  plant  NAAs  like  spilanthol  and  pellitorine  can  enter  the 
systemic circulation via oral, mucosal and dermal administration, after which they could be taken 
up  by  different  organs  including  the  brain,  finally  potentially  interacting  with  different 
pharmacodynamic targets.  
This raises the important question about the regulatory classification of products containing 
these plant-based NAAs (where we will restrict ourselves to the European situation): cosmetics, 
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nutrients/functional food or medicines to name the most important ones, although they can also 
be part of medical devices as an ancillary substance. According to the EU cosmetics regulation 
1223/2009, cosmetics are defined as any substance intended for placing in contact with various 
external parts of the human body or with the teeth or mucus membranes with the purpose to 
clean, to perfume, to change the appearance and to correct body odours, to protect them or keep 
them in good condition [19]. A point of discussion is the situation where a component passes the 
stratum  corneum  and  reaches  viable  cells  and  blood  vessels,  exerting  a  biological-
pharmacological function even in the case the purpose of the product was within the cosmetics 
directive. In this situation, it clearly becomes a borderline product between a cosmetic and a 
medicine, where the general principle in case of doubt is towards the most stringent classification 
(i.e. medicine) to safeguard the consumer. A medicinal product is defined in the consolidated 
European directive 2001/83 (for humans) as any substance presented as having properties for 
treating or preventing disease in human beings/animals, or any substance which may be used in 
or  administered  to  human  beings/animals  either  with  a  view  to  restore,  correct  or  modify 
physiological functions by exerting a pharmacological, immunological or metabolic action, or to 
make a medical diagnosis [20-21]. In other words, next to the presentation criterion, there is also 
the functionality criterion where data indicate plant NAAs are effectively complying to. This is 
confirmed by the herbal Community monographs (well-established or traditional use) of several 
Echinaceae (Coneflower) species, containing i.a. a mixture of tetraene NAAs, established by the 
Committee on Herbal Products (HMPC) at the European Medicines Agency (EMA). Finally, 
there is  also  the possible classification as  food  supplement, nutrient  or functional  food  with 
nutritional  and/or  health  claims  (Directive  2002/46,  Regulation  1924/2006  and  interacting 
directives and regulations like Regulation 907/2013, Regulation 258/97 and Directive 89/398). 
At this moment, no NAA-based products are included in the list in the European claims-register. 
From our own pharmacokinetic results, as well as the available pharmacodynamics literature 
information, it appears that N-alkylamides may currently best be named as cosmenutriceuticals, 
in the cross-region of a cosmetic, functional food nutrient and medicinal product (Figure 9). 
 
Figure 9: NAAs and the different product classes 
 
If more data will become available about this meta-group of biologically active compounds, 
we  can  expect  a  shift  towards  medicines  for  certain  NAAs  under  well-defined  conditions, 
restricting or banning their use in cosmetics or food. Functional Foods in Health and Disease 2014; 4(6):264-275                                                            Page 274 of 275 
 
 
6. CONCLUSION  
NAAs  are  a  diverse  group  of  signaling  plant-derived  secondary  metabolites  which  exhibit 
various functionalities, after administration through various routes. In particular, spilanthol can 
penetrate  the  buccal  mucosa  and  both  spilanthol  and  pellitorine  are  able  to  pass  the  human 
stratum corneum after dermal application and pass the cells of the Caco-2 monolayer gut-model. 
It has been shown that spilanthol, when present in the general blood circulation, crosses the 
blood-brain barrier, thereby possibly eliciting central nervous system effects. 
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